Ex-vivo/in-vitro anti-polyethylene glycol (PEG) immunoglobulin M production from murine splenic B cells stimulated by pegylated liposome

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 11, 2013, Pages 1842-1848

  Lila, Amr Selim Abu ^a,b   Ichihara, Masako ^a   Shimizu, Taro ^a   Ishida, Tatsuhiro ^a   Kiwada, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Zagazig University   (Egypt)

Author keywords

Accelerated blood clearance phenomenon; Antipolyethylene glycol immunoglobulin M; Magnetic cell separator; Marginal zone B cell; Polyethylene glycol

Indexed keywords

CD19 ANTIGEN; CD45RB ANTIGEN; IMMUNOGLOBULIN M; LIPOSOME; MACROGOL; PEGYLATED LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; EX VIVO STUDY; IN VITRO STUDY; MALE; MARGINAL ZONE B CELL; MOUSE; MURINE MODEL; NONHUMAN; SPLEEN CELL; STIMULUS RESPONSE; TIMED DRUG RELEASE;

ANIMALS; B-LYMPHOCYTES; CELLS, CULTURED; IMMUNOGLOBULIN M; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; POLYETHYLENE GLYCOLS; SPLEEN;

EID: 84888580714     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00562     Document Type: Article

References (42)

1. Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J. Control. Release, 161, 461-472 (2012).
2. Payne RW, Murphy BM, Manning MC. Product development issues for PEGylated proteins. Pharm. Dev. Technol., 16, 423-440 (2011).
3. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov., 2, 347-360 (2003).
4. Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int. J. Pharm., 338, 317-326 (2007).
5. Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm. Res., 30, 1729-1734 (2013).
6. Allen C, Dos Santos N, Gallagher R, Chiu GN, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD, Webb MS, Bally MB. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci. Rep., 22, 225-250 (2002).
7. Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv., 13, 399-409 (2006).
8. Torchilin VP. Polymer-coated long-circulating microparticulate pharmaceuticals. J. Microencapsul., 15, 1-19 (1998).
9. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine, 1, 297-315 (2006).
10. Matthews SJ, McCoy C. Peginterferon alfa-2a: a review of approved and investigational uses. Clin. Ther., 26, 991-1025 (2004).
11. Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutierrez-Reyes G, Cortina D, Oregel JA, Perez-Pruna C, Sixtos MS, Cruz-Castellanos S, Soto-Ramirez LE, Rodriguez-Diaz R, Fuentes-Romero L, Gutierrez-Ruiz MC, Kershenobich D. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin. Rev. Invest. Clin., 55, 138-142 (2003).
12. Graham ML. Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev., 55, 1293-1302 (2003).
13. McGahan L. Continuous erythropoietin receptor activator (Mircera) for renal anemia. Issues Emerg. Health Technol., 113, 1-6 (2008).
14. James ND, Coker RJ, Tomlinson D, Harris JR, Gompels M, Pinching AJ, Stewart JS. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. Clin. Oncol. (R Coll Radiol), 6, 294-296 (1994).
15. Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin. Drug Deliv., 9, 1319-1323 (2012).
16. Huang Q, Li D, Kang A, An W, Fan B, Ma X, Ma G, Su Z, Hu T. PEG as a spacer arm markedly increases the immunogenicity of meningococcal group Y polysaccharide conjugate vaccine. J. Control. Release (2013), in press.
17. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res. Ther., 8, R12 (2006).
18. Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, Garratty G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer, 110, 103-111 (2007).
19. Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van Der Meer JW, Corstens FH, Boerman OC. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther., 292, 1071-1079 (2000).
20. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, Corstens FH, Storm G. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J. Pharmacol. Exp. Ther., 298, 607-612 (2001).
21. Ishida T, Masuda K, Ichikawa T, Ichihara M, Irimura K, Kiwada H. Accelerated clearance of a second injection of PEGylated liposomes in mice. Int. J. Pharm., 255, 167-174 (2003).
22. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J. Control. Release, 122, 349-355 (2007).
23. Ishida T, Harada M, Wang XY, Ichihara M, Irimura K, Kiwada H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surfacedensity and chain length of the first-dose liposomes. J. Control. Release, 105, 305-317 (2005).
24. Wang X, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J. Control. Release, 119, 236-244 (2007).
25. Ishida T, Ichihara M, Wang X, Kiwada H. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J. Control. Release, 115, 243-250 (2006).
26. Ichihara M, Shimizu T, Imoto A, Hashiguchi Y, Uehara Y, Ishida T, Kiwada H. Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics, 3, 1-11 (2011).
27. Koide H, Asai T, Hatanaka K, Akai S, Ishii T, Kenjo E, Ishida T, Kiwada H, Tsukada H, Oku N. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int. J. Pharm., 392, 218-223 (2010).
28. Gunzer M, Weishaupt C, Planelles L, Grabbe S. Two-step negative enrichment of CD4+ and CD8+ T cells from murine spleen via nylon wool adherence and an optimized antibody cocktail. J. Immunol. Methods, 258, 55-63 (2001).
29. Peiser M, Grutzkau A, Wanner R, Kolde G. CD1a and CD1c cell sorting yields a homogeneous population of immature human Langerhans cells. J. Immunol. Methods, 279, 41-53 (2003).
30. Meinhardt S, Smiatek J, Eichhorn R, Schmid F. Separation of chiral particles in micro-or nanofluidic channels. Phys. Rev. Lett., 108, 214504 (2012).
31. Ellison CA, Gartner JG. Positive selection of NK1.1+ cells on a magnetic cell separator (MACS). J. Immunol. Methods, 186, 233- 243 (1995).
32. Bartlett GR. Colorimetric assay methods for free and phosphorylated glyceric acids. J. Biol. Chem., 234, 469-471 (1959).
33. Saadati R, Dadashzadeh S, Abbasian Z, Soleimanjahi H. Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: effects of polymer dose, PEG coating, and encapsulated anticancer drug. Pharm. Res., 30, 985-995 (2013).
34. Yang Q, Ma Y, Zhao Y, She Z, Wang L, Li J, Wang C, Deng Y. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy. Int. J. Nanomedicine, 8, 1257-1268 (2013).
35. Koide H, Asai T, Hatanaka K, Urakami T, Ishii T, Kenjo E, Nishihara M, Yokoyama M, Ishida T, Kiwada H, Oku N. Particle sizedependent triggering of accelerated blood clearance phenomenon. Int. J. Pharm., 362, 197-200 (2008).
36. Ishihara T, Takeda M, Sakamoto H, Kimoto A, Kobayashi C, Takasaki N, Yuki K, Tanaka K, Takenaga M, Igarashi R, Maeda T, Yamakawa N, Okamoto Y, Otsuka M, Ishida T, Kiwada H, Mizushima Y, Mizushima T. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm. Res., 26, 2270-2279 (2009).
37. Zandvoort A, Timens W. The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin. Exp. Immunol., 130, 4-11 (2002).
38. Martin F, Oliver AM, Kearney JF. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne par ticulate antigens. Immunity, 14, 617-629 (2001).
39. Won WJ, Kearney JF. CD9 is a unique marker for marginal zone B cells, B1 cells, and plasma cells in mice. J. Immunol., 168, 5605- 5611 (2002).
40. Pillai S, Cariappa A, Moran ST. Marginal zone B cells. Annu. Rev. Immunol., 23, 161-196 (2005).
41. Mandik-Nayak L, Racz J, Sleckman BP, Allen PM. Autoreactive marginal zone B cells are spontaneously activated but lymph node B cells require T cell help. J. Exp. Med., 203, 1985-1998 (2006).
42. Shimizu T, Ishida T, Kiwada H. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon. Immunobiology, 218, 725-732 (2013).